Dr. Larry Kurt Midyett, MD

Dr. Midyett practices at Saint Luke’S Infusion Center - South - HOPD in Overland Park, Kansas.

Dr. Midyett's NPI, 1174555957, was assigned on July 6, 2006. Dr. Midyett graduated from University of Kansas School of Med (KC/Wich/Sal) in 1997. Dr. Midyett holds Kansas license 04-29123.

Dr. Midyett's primary practice is Saint Luke’S Infusion Center - South - HOPD, at 12330 Metcalf Ave, Overland Park, KS 66213.

Dr. Midyett's primary practice is Saint Luke’S Infusion Center - South - HOPD in Overland Park, Kansas. Dr. Midyett is also affiliated with Saint Luke's South Hospital. The medical group on file is Saint Luke's Medical Group. Dmand AI also links Dr. Midyett to 2 more hospitals, 2 medical groups, 1 group practice or clinic and 1 hospital outpatient department, each named with a free account. Dr. Midyett's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Midyett practices, 6 sites in all. Vendor and product names are available with a free account.

Pediatric endocrinology is Dr. Midyett's primary specialty in the NPI Registry, under taxonomy code 2080P0205X. Dr. Midyett is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Midyett's licenses on file in 2 states: Kansas and Missouri.

CMS data shows 386 Medicare services from Dr. Midyett across 7 procedure codes in 2024, for 112 Medicare patients. Medicare paid $19,702 for them. Every service was in an office.

CMS counts 112 Medicare patients who saw Dr. Midyett in 2024. The largest group is 65 to 74, with 62 patients. 73% of them have high cholesterol, and 68% have high blood pressure. 12% are also on Medicaid. Their average risk score is 1.58, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Midyett's median patient age at 28, with 53% women.

In 2024, Dr. Midyett wrote 1,827 Medicare Part D claims for 205 patients. 38% of them were for generic drugs. CMS names the drug for 1,462 of them, across 46 drugs with 11 or more claims each, at $896,192 in total drug cost. In 2023, CMS named 1,180 claims across 38 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Midyett for performance year 2024, reported as part of a group. Dr. Midyett accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Midyett as offering telehealth.

Dmand AI links 6 papers to Dr. Midyett, published from 2011 to 2021. 2021 was the busiest year, with 2. The most frequent topics are Diabetes Mellitus, Type 1, Blood Glucose and Blood Glucose Self-Monitoring. Dr. Midyett has published most often in J Diabetes Sci Technol. Dr. Midyett's most frequent co-authors are Richard M. Bergenstal, MD, Mark A. Clements, MD, PhD and Andrew Joseph Ahmann, MD.

CMS Open Payments shows 671 general payments to Dr. Midyett from 36 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 59% of the total. Abbott Laboratories paid the most, $251,014.

Dr. Midyett graduated from University of Kansas School of Med (KC/Wich/Sal) in 1997.